Stay updated on Nivolumab + Nab-paclitaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + Nab-paclitaxel in NSCLC Clinical Trial page.

Latest updates to the Nivolumab + Nab-paclitaxel in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page footer now shows Revision: v3.6.6, replacing the previous v3.6.5. This indicates a minor site update and does not change the study content or page functionality.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5, indicating a minor page update. The change does not modify trial data or how the page functions.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page footer shows a revision update from v3.6.3 to v3.6.4. This indicates a minor site update and does not modify study details or user-facing content.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page now displays a new site revision tag (v3.6.3) replacing the previous v3.6.2, indicating a software update. This is a metadata-level change rather than a substantive update to study information or layout.SummaryDifference0.1%

- Check73 days agoChange DetectedRevision metadata on the page was updated to v3.6.2, replacing the previous v3.6.0.SummaryDifference0.1%

- Check87 days agoChange DetectedAn explicit recruitment status message ('No longer looking for participants') was added, signaling that the study is no longer enrolling. Additional navigation/help items ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') and a version update (Revision: v3.6.0) were introduced, with a formatting adjustment to the Intervention/Treatment heading.SummaryDifference0.5%

Stay in the know with updates to Nivolumab + Nab-paclitaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + Nab-paclitaxel in NSCLC Clinical Trial page.